Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Derek Yellon

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Procedures

Disorders

Anatomy

Living Beings

Chemicals & Drugs

Physiology

Signal Transduction

Concepts & Ideas

Time Factors

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
46
Hausenloy, Derek
37
Baxter, Gary
31
Mocanu, Mihaela
22
Latchman, David
13
Marber, Michael
13
Davidson, Sean
9
Smith, Christopher
8
Wynne, Abigail
8
Pugsley, Wilfred
7
Ribuot, Christophe
7
Sack, Michael
7
Opie, Lionel
7
Joyeux, Marie
6
Downey, James
6
Dana, A

Sign-in to see all Coauthors

Publications

TOP 3
Lim Shiang Y; Davidson Sean M; Yellon Derek M; Smith Christopher C T
The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction.
Venugopal V; Hausenloy D J; Ludman A; Di Salvo C; Kolvekar S; Yap J; Lawrence D; Bognolo J; Yellon D M
Remote ischaemic preconditioning reduces myocardial injury in patients undergoing cardiac surgery with cold-blood cardioplegia: a randomised controlled trial.
Hausenloy Derek J; Yellon Derek M
Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Derek Yellon (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Lim Shiang Y; Davidson Sean M; Yellon Derek M; Smith Christopher C T
The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction.
Basic research in cardiology 2009;104(6):781-92.
2009: Venugopal V; Hausenloy D J; Ludman A; Di Salvo C; Kolvekar S; Yap J; Lawrence D; Bognolo J; Yellon D M
Remote ischaemic preconditioning reduces myocardial injury in patients undergoing cardiac surgery with cold-blood cardioplegia: a randomised controlled trial.
Heart (British Cardiac Society) 2009;95(19):1567-71.
2009: Hausenloy Derek J; Yellon Derek M
Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.
Current opinion in cardiology 2009;24(5):473-82.
2009: Hausenloy Derek J; Yellon Derek M
Cardioprotective growth factors.
Cardiovascular research 2009;83(2):179-94.
2009: Venugopal Vinod; Ludman Andrew; Yellon Derek M; Hausenloy Derek J
'Conditioning' the heart during surgery.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2009;35(6):977-87.
2009: Hausenloy Derek J; Yellon Derek M
Preconditioning and postconditioning: underlying mechanisms and clinical application.
Atherosclerosis 2009;204(2):334-41.
2009: Paiva Marta; Riksen Niels P; Davidson Sean M; Hausenloy Derek J; Monteiro Pedro; Gonçalves Lino; Providência Luís; Rongen Gerard A; Smits Paul; Mocanu Mihaela M; Yellon Derek M
Metformin prevents myocardial reperfusion injury by activating the adenosine receptor.
Journal of cardiovascular pharmacology 2009;53(5):373-8.
2009: Sivaraman Vivek; Hausenloy Derek J; Kolvekar Shyam; Hayward Martin; Yap John; Lawrence David; Di Salvo Carmelo; Yellon Derek M
The divergent roles of protein kinase C epsilon and delta in simulated ischaemia-reperfusion injury in human myocardium.
Journal of molecular and cellular cardiology 2009;46(5):758-64.
2009: Dixon Richard A; Davidson Sean M; Wynne Abigail M; Yellon Derek M; Smith Christopher C T
The cardioprotective actions of leptin are lost in the Zucker obese (fa/fa) rat.
Journal of cardiovascular pharmacology 2009;53(4):311-7.
2009: Ludman Andrew; Venugopal Vinod; Yellon Derek M; Hausenloy Derek J
Statins and cardioprotection--more than just lipid lowering?
Pharmacology & therapeutics 2009;122(1):30-43.
2009: Ludman Andrew J; Hausenloy Derek J; Venugopal Vinod; Yellon Derek M
Premature meta-analysis of remote ischemic preconditioning.
The American journal of cardiology 2009;103(6):893-4.
2009: Hausenloy Derek J; Ong Sang-Bing; Yellon Derek M
The mitochondrial permeability transition pore as a target for preconditioning and postconditioning.
Basic research in cardiology 2009;104(2):189-202.
2009: Davidson Sean M; Yellon Derek M
Urocortin: a protective peptide that targets both the myocardium and vasculature.
Pharmacological reports : PR 2009;61(1):172-82.
2009: Mocanu Mihaela M; Yellon Derek M
Letter to the editor: "Zinc and cardioprotection: the missing link".
American journal of physiology. Heart and circulatory physiology 2009;296(1):H233-4; author reply H235.
2008: Siddall Hilary K; Warrell Clare E; Davidson Sean M; Mocanu Mihaela M; Yellon Derek M
Mitochondrial PINK1--a novel cardioprotective kinase?
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2008;22(6):507-8.
2008: Siddall Hilary K; Warrell Clare E; Yellon Derek M; Mocanu Mihaela M
Ischemia-reperfusion injury and cardioprotection: investigating PTEN, the phosphatase that negatively regulates PI3K, using a congenital model of PTEN haploinsufficiency.
Basic research in cardiology 2008;103(6):560-8.
2008: Hausenloy Derek J; Yellon Derek M
GLP-1 therapy: beyond glucose control.
Circulation. Heart failure 2008;1(3):147-9.
2008: Hausenloy Derek J; Yellon Derek M
Clinical translation of cardioprotective strategies : report and recommendations of the Hatter Institute 5th International Workshop on Cardioprotection.
Basic research in cardiology 2008;103(5):493-500.
2008: Nishino Yasuhiro; Webb Ian G; Davidson Sean M; Ahmed Aminul I; Clark James E; Jacquet Sebastien; Shah Ajay M; Miura Tetsuji; Yellon Derek M; Avkiran Metin; Marber Michael S
Glycogen synthase kinase-3 inactivation is not required for ischemic preconditioning or postconditioning in the mouse.
Circulation research 2008;103(3):307-14.
2008: Hausenloy Derek J; Yellon Derek M
Remote ischaemic preconditioning: underlying mechanisms and clinical application.
Cardiovascular research 2008;79(3):377-86.
2008: Riksen Niels P; Hausenloy Derek J; Yellon Derek M
Wake up and smell the coffee: yet another no go for cardiac patients? : editorial to "caffeinated coffee blunts the myocardial protective effects of statins against ischemia-reperfusion injury in the rat" by Ye et al.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2008;22(4):257-9.
2008: Lim Shiang Y; Davidson Sean M; Paramanathan Ajeev J; Smith Christopher C T; Yellon Derek M; Hausenloy Derek J
The novel adipocytokine visfatin exerts direct cardioprotective effects.
Journal of cellular and molecular medicine 2008;12(4):1395-403.
2008: Hausenloy Derek J; Yellon Derek M
Time to take myocardial reperfusion injury seriously.
The New England journal of medicine 2008;359(5):518-20.
2008: Hausenloy D J; Yellon D M
Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Heart (British Cardiac Society) 2008;94(6):706-14.
2008: Hausenloy D J; Yellon D M
Preconditioning and postconditioning: new strategies for cardioprotection.
Diabetes, obesity & metabolism 2008;10(6):451-9.
2008: Riksen Niels P; Hausenloy Derek J; Yellon Derek M
Erythropoietin: ready for prime-time cardioprotection.
Trends in pharmacological sciences 2008;29(5):258-67.
2008: Bhamra Gurpreet S; Hausenloy Derek J; Davidson Sean M; Carr Richard D; Paiva Marta; Wynne Abigail M; Mocanu Mihaela M; Yellon Derek M
Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening.
Basic research in cardiology 2008;103(3):274-84.
2008: Mudalagiri N R; Mocanu M M; Di Salvo C; Kolvekar S; Hayward M; Yap J; Keogh B; Yellon D M
Erythropoietin protects the human myocardium against hypoxia/reoxygenation injury via phosphatidylinositol-3 kinase and ERK1/2 activation.
British journal of pharmacology 2008;153(1):50-6.
2007: Lim S Y; Davidson S M; Mocanu M M; Yellon D M; Smith C C T
The cardioprotective effect of necrostatin requires the cyclophilin-D component of the mitochondrial permeability transition pore.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2007;21(6):467-9.
2007: Smith Christopher C T; Mocanu Michaela M; Bowen Jonathan; Wynne Abigail M; Simpkin James C; Dixon Richard A; Cooper Michael B; Yellon Derek M
Temporal changes in myocardial salvage kinases during reperfusion following ischemia: studies involving the cardioprotective adipocytokine apelin.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2007;21(6):409-14.
2007: Hausenloy Derek J; Yellon Derek M
Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection.
Heart failure reviews 2007;12(3-4):217-34.
2007: Simpkin James C; Yellon Derek M; Davidson Sean M; Lim Shiang Y; Wynne Abigail M; Smith Christopher C T
Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury.
Basic research in cardiology 2007;102(6):518-28.
2007: Hausenloy Derek J; Yellon Derek M
Preconditioning and postconditioning: united at reperfusion.
Pharmacology & therapeutics 2007;116(2):173-91.
2007: Mocanu Mihaela M; Shakkottai Padmanabhan; Yellon Derek M
The power of drug co-administration: smaller doses better outcomes.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2007;21(5):319-20.
2007: Yellon Derek M; Hausenloy Derek J
Myocardial reperfusion injury.
The New England journal of medicine 2007;357(11):1121-35.
2007: Loukogeorgakis Stavros P; Williams Rupert; Panagiotidou Anna T; Kolvekar Shyamsunder K; Donald Ann; Cole Tim J; Yellon Derek M; Deanfield John E; MacAllister Raymond J
Transient limb ischemia induces remote preconditioning and remote postconditioning in humans by a K(ATP)-channel dependent mechanism.
Circulation 2007;116(12):1386-95.
2007: Sivaraman Vivek; Mudalagiri Naveen R; Di Salvo Carmelo; Kolvekar Shyam; Hayward Martin; Yap John; Keogh Bruce; Hausenloy Derek J; Yellon Derek M
Postconditioning protects human atrial muscle through the activation of the RISK pathway.
Basic research in cardiology 2007;102(5):453-9.
2007: Hausenloy Derek J; Wynne Abigail M; Yellon Derek M
Ischemic preconditioning targets the reperfusion phase.
Basic research in cardiology 2007;102(5):445-52.
2007: Hausenloy Derek J; Mwamure Peter K; Venugopal Vinod; Harris Joanne; Barnard Matthew; Grundy Ernie; Ashley Elizabeth; Vichare Sanjeev; Di Salvo Carmelo; Kolvekar Shyam; Hayward Martin; Keogh Bruce; MacAllister Raymond J; Yellon Derek M
Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial.
Lancet 2007;370(9587):575-9.
2007: Smith Christopher C T; Davidson Sean M; Lim Shiang Y; Simpkin James C; Hothersall John S; Yellon Derek M
Necrostatin: a potentially novel cardioprotective agent?
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2007;21(4):227-33.
2007: Bose Amal K; Mocanu Mihaela M; Carr Richard D; Yellon Derek M
Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2007;21(4):253-6.
2007: Ebrahim Zaileen; Yellon Derek M; Baxter Gary F
Ischemic preconditioning is lost in aging hypertensive rat heart: independent effects of aging and longstanding hypertension.
Experimental gerontology 2007;42(8):807-14.
2007: Lim Shiang Y; Davidson Sean M; Hausenloy Derek J; Yellon Derek M
Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore.
Cardiovascular research 2007;75(3):530-5.
2007: Hausenloy Derek J; Yellon Derek M
The evolving story of "conditioning" to protect against acute myocardial ischaemia-reperfusion injury.
Heart (British Cardiac Society) 2007;93(6):649-51.
2007: Minners Jan; Lacerda Lydia; Yellon Derek M; Opie Lionel H; McLeod Christopher J; Sack Michael N
Diazoxide-induced respiratory inhibition - a putative mitochondrial K(ATP) channel independent mechanism of pharmacological preconditioning.
Molecular and cellular biochemistry 2007;294(1-2):11-8.
2007: Ebrahim Zaileen; Yellon Derek M; Baxter Gary F
Attenuated cardioprotective response to bradykinin, but not classical ischaemic preconditioning, in DOCA-salt hypertensive left ventricular hypertrophy.
Pharmacological research : the official journal of the Italian Pharmacological Society 2007;55(1):42-8.
2006: Smith C C T; Mocanu M M; Davidson S M; Wynne A M; Simpkin J C; Yellon D M
Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects.
British journal of pharmacology 2006;149(1):5-13.
2006: Davidson Sean M; Yellon Derek M
Does hyperglycemia reduce proliferation or increase apoptosis?
American journal of physiology. Heart and circulatory physiology 2006;291(3):H1486; author reply H1487.
2006: Hausenloy Derek J; Mocanu Mihaela M; Yellon Derek M
Is this truly ischemic preconditioning?
Circulation research 2006;99(4):e11.
2006: Davidson Sean M; Yellon Derek M
Dissecting out the mechanism of cardioprotection by endogenous erthyropoietin using genetic engineering.
Cardiovascular research 2006;71(3):408-10.
2006: Mocanu Mihaela M; Field Duncan C; Yellon Derek M
A potential role for PTEN in the diabetic heart.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2006;20(4):319-21.
2006: Hausenloy Derek J; Yellon Derek M
Survival kinases in ischemic preconditioning and postconditioning.
Cardiovascular research 2006;70(2):240-53.
2006: Davidson Sean M; Hausenloy Derek; Duchen Michael R; Yellon Derek M
Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection.
The international journal of biochemistry & cell biology 2006;38(3):414-9.
2006: Loukogeorgakis Stavros P; Panagiotidou Anna T; Yellon Derek M; Deanfield John E; MacAllister Raymond J
Postconditioning protects against endothelial ischemia-reperfusion injury in the human forearm.
Circulation 2006;113(7):1015-9.
2006: Yellon Derek M; Opie Lionel H
Postconditioning for protection of the infarcting heart.
Lancet 2006;367(9509):456-8.
2005: Wynne Abigail M; Mocanu Mihaela M; Yellon Derek M
Pioglitazone mimics preconditioning in the isolated perfused rat heart: a role for the prosurvival kinases PI3K and P42/44MAPK.
Journal of cardiovascular pharmacology 2005;46(6):817-22.
2005: Yellon Derek M; Hausenloy Derek J
Realizing the clinical potential of ischemic preconditioning and postconditioning.
Nature clinical practice. Cardiovascular medicine 2005;2(11):568-75.
2005: Vinten-Johansen Jakob; Yellon Derek M; Opie Lionel H
Postconditioning: a simple, clinically applicable procedure to improve revascularization in acute myocardial infarction.
Circulation 2005;112(14):2085-8.
2005: Davidson Sean M; Yellon Derek M
The role of nitric oxide in mitochondria. Focus on "Modulation of mitochondrial Ca2+ by nitric oxide in cultured bovine vascular endothelial cells".
American journal of physiology. Cell physiology 2005;289(4):C775-7.
2005: Bullard A J; Govewalla P; Yellon D M
Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo.
Basic research in cardiology 2005;100(5):397-403.
2005: Fauchon M A C; Pell T J; Baxter G F; Yellon D M; Latchman D S; Hubank M F; Mayne L V
Representational difference analysis of cDNA identifies novel genes expressed following preconditioning of the heart.
Experimental & molecular medicine 2005;37(4):311-22.
2005: Tsang Andrew; Hausenloy Derek J; Mocanu Mihaela M; Carr Richard D; Yellon Derek M
Preconditioning the diabetic heart: the importance of Akt phosphorylation.
Diabetes 2005;54(8):2360-4.
2005: Shanmuganathan Selvaraj; Hausenloy Derek J; Duchen Michael R; Yellon Derek M
Mitochondrial permeability transition pore as a target for cardioprotection in the human heart.
American journal of physiology. Heart and circulatory physiology 2005;289(1):H237-42.
2005: Tsang Andrew; Hausenloy Derek J; Yellon Derek M
Myocardial postconditioning: reperfusion injury revisited.
American journal of physiology. Heart and circulatory physiology 2005;289(1):H2-7.
2005: Hausenloy D J; Yellon D M
Protecting the myocardium at time of reperfusion--Meeting report of the Hatter Institute 4th International Workshop on Cardio-protection.
Basic research in cardiology 2005;100(4):383-6.
2005: Mensah Kwabena; Mocanu Mihaela M; Yellon Derek M
Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten?
Journal of the American College of Cardiology 2005;45(8):1287-91.
2005: Efthymiou Christopher A; Mocanu Mihaela M; Yellon Derek M
Atorvastatin and myocardial reperfusion injury: new pleiotropic effect implicating multiple prosurvival signaling.
Journal of cardiovascular pharmacology 2005;45(3):247-52.
2005: Hausenloy Derek J; Tsang Andrew; Yellon Derek M
The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning.
Trends in cardiovascular medicine 2005;15(2):69-75.
2005: Hausenloy Derek J; Tsang A; Mocanu Mihaela M; Yellon Derek M
Ischemic preconditioning protects by activating prosurvival kinases at reperfusion.
American journal of physiology. Heart and circulatory physiology 2005;288(2):H971-6.
2005: Bose Amal K; Mocanu Mihaela M; Carr Richard D; Yellon Derek M
Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2005;19(1):9-11.
2005: Bose Amal K; Mocanu Mihaela M; Carr Richard D; Brand Christian L; Yellon Derek M
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.
Diabetes 2005;54(1):146-51.
2004: Efthymiou Christopher A; Mocanu Mihaela M; de Belleroche Jackie; Wells Dominic J; Latchmann David S; Yellon Derek M
Heat shock protein 27 protects the heart against myocardial infarction.
Basic research in cardiology 2004;99(6):392-4.
2004: Hausenloy Derek J; Mocanu Mihaela M; Yellon Derek M
Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning.
Cardiovascular research 2004;63(2):305-12.
2004: Tsang Andrew; Hausenloy Derek J; Mocanu Mihaela M; Yellon Derek M
Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway.
Circulation research 2004;95(3):230-2.
2004: Hausenloy Derek J; Yellon Derek M; Mani-Babu Siva; Duchen Michael R
Preconditioning protects by inhibiting the mitochondrial permeability transition.
American journal of physiology. Heart and circulatory physiology 2004;287(2):H841-9.
2004: Hausenloy Derek; Wynne Abigail; Duchen Michael; Yellon Derek
Transient mitochondrial permeability transition pore opening mediates preconditioning-induced protection.
Circulation 2004;109(14):1714-7.
2004: Ebrahim Z; Baxter G F; Yellon D M
Omapatrilat limits infarct size and lowers the threshold for induction of myocardial preconditioning through a bradykinin receptor-mediated mechanism.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2004;18(2):127-34.
2004: Maddock Helen L; Siedlecka Sylvia M; Yellon Derek M
Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2004;18(2):113-9.
2004: Hausenloy Derek J; Yellon Derek M
New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway.
Cardiovascular research 2004;61(3):448-60.
2004: Hausenloy Derek J; Yellon Derek M
Adenosine-induced second window of protection is mediated by inhibition of mitochondrial permeability transition pore opening at the time of reperfusion.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2004;18(1):79-80.
2003: Hausenloy Derek J; Duchen Michael R; Yellon Derek M
Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury.
Cardiovascular research 2003;60(3):617-25.
2003: Mocanu Mihaela M; Yellon Derek M
p53 down-regulation: a new molecular mechanism involved in ischaemic preconditioning.
FEBS letters 2003;555(2):302-6.
2003: Yellon Derek M; Downey James M
Preconditioning the myocardium: from cellular physiology to clinical cardiology.
Physiological reviews 2003;83(4):1113-51.
2003: Kis Adrienn; Baxter Gary F; Yellon Derek M
Limitation of myocardial reperfusion injury by AMP579, an adenosine A1/A2A receptor agonist: role of A2A receptor and Erk1/2.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2003;17(5-6):415-25.
2003: Kis Adrienn; Yellon Derek M; Baxter Gary F
Second window of protection following myocardial preconditioning: an essential role for PI3 kinase and p70S6 kinase.
Journal of molecular and cellular cardiology 2003;35(9):1063-71.
2003: D'Souza Savio P; Yellon Derek M; Martin Claus; Schulz Rainer; Heusch Gerd; Onody Annamaria; Ferdinandy Peter; Baxter Gary F
B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening.
American journal of physiology. Heart and circulatory physiology 2003;284(5):H1592-600.
2003: Sack Michael N; Yellon Derek M
Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation.
Journal of the American College of Cardiology 2003;41(8):1404-7.
2003: Hausenloy Derek J; Yellon Derek M
The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion.
Journal of molecular and cellular cardiology 2003;35(4):339-41.
2003: Baxter Gary F; Yellon Derek M
Current trends and controversies in ischemia-reperfusion research--meeting report of the Hatter Institute 3rd International Workshop on Cardioprotection.
Basic research in cardiology 2003;98(2):133-6.
2003: Kis Adrienn; Yellon Derek M; Baxter Gary F
Role of nuclear factor-kappa B activation in acute ischaemia-reperfusion injury in myocardium.
British journal of pharmacology 2003;138(5):894-900.
2003: Bell Robert M; Yellon Derek M
Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS.
Journal of molecular and cellular cardiology 2003;35(2):185-93.
2003: Bell Robert M; Yellon Derek M
Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway.
Journal of the American College of Cardiology 2003;41(3):508-15.
2003: Bell Robert M; Maddock Helen L; Yellon Derek M
The cardioprotective and mitochondrial depolarising properties of exogenous nitric oxide in mouse heart.
Cardiovascular research 2003;57(2):405-15.
2002: Taggart Peter; Yellon Derek M
Preconditioning and arrhythmias.
Circulation 2002;106(24):2999-3001.
2002: Schulman Daniel; Latchman David S; Yellon Derek M
Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway.
American journal of physiology. Heart and circulatory physiology 2002;283(4):H1481-8.
2002: Maddock Helen L; Mocanu Mihaela M; Yellon Derek M
Adenosine A(3) receptor activation protects the myocardium from reperfusion/reoxygenation injury.
American journal of physiology. Heart and circulatory physiology 2002;283(4):H1307-13.
2002: Hausenloy Derek J; Maddock Helen L; Baxter Gary F; Yellon Derek M
Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?
Cardiovascular research 2002;55(3):534-43.
2002: Oldenburg Olaf; Cohen Michael V; Yellon Derek M; Downey James M
Mitochondrial K(ATP) channels: role in cardioprotection.
Cardiovascular research 2002;55(3):429-37.
2002: Yellon Derek M; Downey James M
Spotlight on preconditioning.
Cardiovascular research 2002;55(3):425-8.
2002: Mocanu Mihaela M; Bell Robert M; Yellon Derek M
PI3 kinase and not p42/p44 appears to be implicated in the protection conferred by ischemic preconditioning.
Journal of molecular and cellular cardiology 2002;34(6):661-8.
2002: Teoh L K K; Grant R; Hulf J A; Pugsley W B; Yellon D M
A comparison between ischemic preconditioning, intermittent cross-clamp fibrillation and cold crystalloid cardioplegia for myocardial protection during coronary artery bypass graft surgery.
Cardiovascular surgery (London, England) 2002;10(3):251-5.
2002: Liao Zhihong; Brar Bhawanjit K; Cai Qing; Stephanou Anastasis; O'Leary Rhona M; Pennica Diane; Yellon Derek M; Latchman David S
Cardiotrophin-1 (CT-1) can protect the adult heart from injury when added both prior to ischaemia and at reperfusion.
Cardiovascular research 2002;53(4):902-10.
2002: Bell Robert M; Smith Christopher C T; Yellon Derek M
Nitric oxide as a mediator of delayed pharmacological (A(1) receptor triggered) preconditioning; is eNOS masquerading as iNOS?
Cardiovascular research 2002;53(2):405-13.
2002: Teoh L K K; Grant R; Hulf J A; Pugsley W B; Yellon D M
The effect of preconditioning (ischemic and pharmacological) on myocardial necrosis following coronary artery bypass graft surgery.
Cardiovascular research 2002;53(1):175-80.
2001: Jonassen A K; Sack M N; Mjøs O D; Yellon D M
Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling.
Circulation research 2001;89(12):1191-8.
2001: Bell R M; Yellon D M
The contribution of endothelial nitric oxide synthase to early ischaemic preconditioning: the lowering of the preconditioning threshold. An investigation in eNOS knockout mice.
Cardiovascular research 2001;52(2):274-80.
2001: Minners J; Lacerda L; McCarthy J; Meiring J J; Yellon D M; Sack M N
Ischemic and pharmacological preconditioning in Girardi cells and C2C12 myotubes induce mitochondrial uncoupling.
Circulation research 2001;89(9):787-92.
2001: Schulman D; Latchman D S; Yellon D M
Effect of aging on the ability of preconditioning to protect rat hearts from ischemia-reperfusion injury.
American journal of physiology. Heart and circulatory physiology 2001;281(4):H1630-6.
2001: Carroll R; Gant V A; Yellon D M
Mitochondrial K(ATP) channel opening protects a human atrial-derived cell line by a mechanism involving free radical generation.
Cardiovascular research 2001;51(4):691-700.
2001: Ebrahim Z; Yellon D M; Baxter G F
Bradykinin elicits "second window" myocardial protection in rat heart through an NO-dependent mechanism.
American journal of physiology. Heart and circulatory physiology 2001;281(3):H1458-64.
2001: Dana A; Baxter G F; Yellon D M
Delayed or second window preconditioning induced by adenosine A1 receptor activation is independent of early generation of nitric oxide or late induction of inducible nitric oxide synthase.
Journal of cardiovascular pharmacology 2001;38(2):278-87.
2001: Brar B K; Stephanou A; Liao Z; O'Leary R M; Pennica D; Yellon D M; Latchman D S
Cardiotrophin-1 can protect cardiac myocytes from injury when added both prior to simulated ischaemia and at reoxygenation.
Cardiovascular research 2001;51(2):265-74.
2001: Mocanu M M; Maddock H L; Baxter G F; Lawrence C L; Standen N B; Yellon D M
Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide.
Circulation 2001;103(25):3111-6.
2001: Yamashita N; Baxter G F; Yellon D M
Exercise directly enhances myocardial tolerance to ischaemia-reperfusion injury in the rat through a protein kinase C mediated mechanism.
Heart (British Cardiac Society) 2001;85(3):331-6.
2000: Mocanu M M; Baxter G F; Yue Y; Critz S D; Yellon D M
The p38 MAPK inhibitor, SB203580, abrogates ischaemic preconditioning in rat heart but timing of administration is critical.
Basic research in cardiology 2000;95(6):472-8.
2000: Bell S P; Sack M N; Patel A; Opie L H; Yellon D M
Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle.
Journal of the American College of Cardiology 2000;36(7):2296-302.
2000: Yellon D M; Dana A
The preconditioning phenomenon: A tool for the scientist or a clinical reality?
Circulation research 2000;87(7):543-50.
2000: Joyeux M; Arnaud C; Richard M J; Yellon D M; Demenge P; Ribuot C
Effect of okadaic acid, a protein phosphatase inhibitor, on heat stress-induced HSP72 synthesis and thermotolerance.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2000;14(4):441-6.
2000: Yellon D M; Baxter G F
Sodium-hydrogen exchange in myocardial reperfusion injury.
Lancet 2000;356(9229):522-3.
2000: Minners J; van den Bos E J; Yellon D M; Schwalb H; Opie L H; Sack M N
Dinitrophenol, cyclosporin A, and trimetazidine modulate preconditioning in the isolated rat heart: support for a mitochondrial role in cardioprotection.
Cardiovascular research 2000;47(1):68-73.
2000: Joyeux M; Boumendjel A; Carroll R; Ribuot C; Godin-Ribuot D; Yellon D M
SB 203580, a mitogen-activated protein kinase inhibitor, abolishes resistance to myocardial infarction induced by heat stress.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2000;14(3):337-43.
2000: Carroll R; Yellon D M
Delayed cardioprotection in a human cardiomyocyte-derived cell line: the role of adenosine, p38MAP kinase and mitochondrial KATP.
Basic research in cardiology 2000;95(3):243-9.
2000: Dana A; Jonassen A K; Yamashita N; Yellon D M
Adenosine A(1) receptor activation induces delayed preconditioning in rats mediated by manganese superoxide dismutase.
Circulation 2000;101(24):2841-8.
2000: Rubino A; Yellon D M
Ischaemic preconditioning of the vasculature: an overlooked phenomenon for protecting the heart?
Trends in pharmacological sciences 2000;21(6):225-30.
2000: Dana A; Skarli M; Papakrivopoulou J; Yellon D M
Adenosine A(1) receptor induced delayed preconditioning in rabbits: induction of p38 mitogen-activated protein kinase activation and Hsp27 phosphorylation via a tyrosine kinase- and protein kinase C-dependent mechanism.
Circulation research 2000;86(9):989-97.
2000: Jonassen A K; Brar B K; Mjøs O D; Sack M N; Latchman D S; Yellon D M
Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism.
Journal of molecular and cellular cardiology 2000;32(5):757-64.
2000: Stephanou A; Brar B K; Scarabelli T M; Jonassen A K; Yellon D M; Marber M S; Knight R A; Latchman D S
Ischemia-induced STAT-1 expression and activation play a critical role in cardiomyocyte apoptosis.
The Journal of biological chemistry 2000;275(14):10002-8.
2000: Yellon D M; Baxter G F
Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: distant dream or near reality?
Heart (British Cardiac Society) 2000;83(4):381-7.
2000: Brar B K; Jonassen A K; Stephanou A; Santilli G; Railson J; Knight R A; Yellon D M; Latchman D S
Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway.
The Journal of biological chemistry 2000;275(12):8508-14.
2000: Sack M N; Harrington L S; Jonassen A K; Mjøs O D; Yellon D M
Coordinate regulation of metabolic enzyme encoding genes during cardiac development and following carvedilol therapy in spontaneously hypertensive rats.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2000;14(1):31-9.
2000: Aitchison K A; Baxter G F; Awan M M; Smith R M; Yellon D M; Opie L H
Opposing effects on infarction of delta and kappa opioid receptor activation in the isolated rat heart: implications for ischemic preconditioning.
Basic research in cardiology 2000;95(1):1-10; discussion 11.
2000: Sumeray M S; Rees D D; Yellon D M
Infarct size and nitric oxide synthase in murine myocardium.
Journal of molecular and cellular cardiology 2000;32(1):35-42.
1999: Yellon D M; Baxter G F
Reperfusion injury revisited: is there a role for growth factor signaling in limiting lethal reperfusion injury?
Trends in cardiovascular medicine 1999;9(8):245-9.
1999: Joyeux M; Faure P; Godin-Ribuot D; Halimi S; Patel A; Yellon D M; Demenge P; Ribuot C
Heat stress fails to protect myocardium of streptozotocin-induced diabetic rats against infarction.
Cardiovascular research 1999;43(4):939-46.
1999: Baxter G F; Yellon D M
ATP-sensitive K+ channels mediate the delayed cardioprotective effect of adenosine A1 receptor activation.
Journal of molecular and cellular cardiology 1999;31(5):981-9.
1999: Mocanu M M; Gadgil S; Yellon D M; Baxter G F
Mibefradil, a T-type and L-type calcium channel blocker, limits infarct size through a glibenclamide-sensitive mechanism.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1999;13(2):115-22.
1999: Carroll R; Yellon D M
Myocardial adaptation to ischaemia--the preconditioning phenomenon.
International journal of cardiology 1999;68 Suppl 1():S93-101.
1999: Awan M M; Taunyane C; Aitchison K A; Yellon D M; Opie L H
Normothermic transfer times up to 3 min will not precondition the isolated rat heart.
Journal of molecular and cellular cardiology 1999;31(3):503-11.
1999: Imagawa J; Yellon D M; Baxter G F
Pharmacological evidence that inducible nitric oxide synthase is a mediator of delayed preconditioning.
British journal of pharmacology 1999;126(3):701-8.
1999: Joyeux M; Godin-Ribuot D; Yellon D M; Demenge P; Ribuot C
Heat stress response and myocardial protection.
Fundamental & clinical pharmacology 1999;13(1):1-10.
1998: Dana A; Yellon D M
Angina: who needs it? Cardioprotection in the preconditioning era.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1998;12(6):515-28.
1998: Pell T J; Baxter G F; Yellon D M; Drew G M
Renal ischemia preconditions myocardium: role of adenosine receptors and ATP-sensitive potassium channels.
The American journal of physiology 1998;275(5 Pt 2):H1542-7.
1998: Joyeux M; Lagneux C; Bricca G; Yellon D M; Demenge P; Ribuot C
Heat stress-induced resistance to myocardial infarction in the isolated heart from transgenic [(mREN-2)27] hypertensive rats.
Cardiovascular research 1998;40(1):124-30.
1998: Sumeray M S; Yellon D M
Ischaemic preconditioning reduces infarct size following global ischaemia in the murine myocardium.
Basic research in cardiology 1998;93(5):384-90.
1998: Joyeux M; Godin-Ribuot D; Patel A; Demenge P; Yellon D M; Ribuot C
Infarct size-reducing effect of heat stress and alpha1 adrenoceptors in rats.
British journal of pharmacology 1998;125(4):645-50.
1998: Dana A; Baxter G F; Walker J M; Yellon D M
Prolonging the delayed phase of myocardial protection: repetitive adenosine A1 receptor activation maintains rabbit myocardium in a preconditioned state.
Journal of the American College of Cardiology 1998;31(5):1142-9.
1998: Dana A; Sumeray M S; Yellon D M
Ischaemic preconditioning: a clinical perspective.
Hospital medicine (London, England : 1998) 1998;59(3):216-20.
1998: Yellon D M; Baxter G F; Garcia-Dorado D; Heusch G; Sumeray M S
Ischaemic preconditioning: present position and future directions.
Cardiovascular research 1998;37(1):21-33.
1998: Imagawa J; Baxter G F; Yellon D M
Myocardial protection afforded by nicorandil and ischaemic preconditioning in a rabbit infarct model in vivo.
Journal of cardiovascular pharmacology 1998;31(1):74-9.
1997: Joyeux M; Baxter G F; Thomas D L; Ribuot C; Yellon D M
Protein kinase C is involved in resistance to myocardial infarction induced by heat stress.
Journal of molecular and cellular cardiology 1997;29(12):3311-9.
1997: Pell T J; Yellon D M; Goodwin R W; Baxter G F
Myocardial ischemic tolerance following heat stress is abolished by ATP-sensitive potassium channel blockade.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1997;11(5):679-86.
1997: Carr C S; Hill R J; Masamune H; Kennedy S P; Knight D R; Tracey W R; Yellon D M
Evidence for a role for both the adenosine A1 and A3 receptors in protection of isolated human atrial muscle against simulated ischaemia.
Cardiovascular research 1997;36(1):52-9.
1997: Carr C S; Yellon D M
Ischaemic preconditioning may abolish the protection afforded by ATP-sensitive potassium channel openers in isolated human atrial muscle.
Basic research in cardiology 1997;92(4):252-60.
1997: Carr C S; Grover G J; Pugsley W B; Yellon D M
Comparison of the protective effects of a highly selective ATP-sensitive potassium channel opener and ischemic preconditioning in isolated human atrial muscle.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1997;11(3):473-8.
1997: Baxter G F; Mocanu M M; Yellon D M
Attenuation of myocardial ischaemic injury 24 h after diacylglycerol treatment in vivo.
Journal of molecular and cellular cardiology 1997;29(7):1967-75.
1997: Imagawa J i; Baxter G F; Yellon D M
Genistein, a tyrosine kinase inhibitor, blocks the "second window of protection" 48 h after ischemic preconditioning in the rabbit.
Journal of molecular and cellular cardiology 1997;29(7):1885-93.
1997: Baxter G F; Goma F M; Yellon D M
Characterisation of the infarct-limiting effect of delayed preconditioning: timecourse and dose-dependency studies in rabbit myocardium.
Basic research in cardiology 1997;92(3):159-67.
1997: Morris S D; Yellon D M
Angiotensin-converting enzyme inhibitors potentiate preconditioning through bradykinin B2 receptor activation in human heart.
Journal of the American College of Cardiology 1997;29(7):1599-606.
1997: Baxter G F; Yellon D M
Time course of delayed myocardial protection after transient adenosine A1-receptor activation in the rabbit.
Journal of cardiovascular pharmacology 1997;29(5):631-8.
1997: Jenkins D P; Pugsley W B; Alkhulaifi A M; Kemp M; Hooper J; Yellon D M
Ischaemic preconditioning reduces troponin T release in patients undergoing coronary artery bypass surgery.
Heart (British Cardiac Society) 1997;77(4):314-8.
1997: Sumeray M S; Yellon D M
Myocardial preconditioning. What have we learned?
European heart journal 1997;18 Suppl A():A8-14.
1996: Cumming D V; Heads R J; Watson A; Latchman D S; Yellon D M
Differential protection of primary rat cardiocytes by transfection of specific heat stress proteins.
Journal of molecular and cellular cardiology 1996;28(12):2343-9.
1996: Baxter G F; Heads R J; Yellon D M
Oxidative stress and the second window of protection after preconditioning.
Circulation 1996;94(11):2992-3.
1996: Cumming D V; Heads R J; Coffin R S; Yellon D M; Latchman D S
Pharmacological preconditioning of primary rat cardiac myocytes by FK506.
Basic research in cardiology 1996;91(5):367-73.
1996: Coffin R S; Howard M K; Cumming D V; Dollery C M; McEwan J; Yellon D M; Marber M S; MacLean A R; Brown S M; Latchman D S
Gene delivery to the heart in vivo and to cardiac myocytes and vascular smooth muscle cells in vitro using herpes virus vectors.
Gene therapy 1996;3(7):560-6.
1996: Yang X M; Baxter G F; Heads R J; Yellon D M; Downey J M; Cohen M V
Infarct limitation of the second window of protection in a conscious rabbit model.
Cardiovascular research 1996;31(5):777-83.
1996: Baxter G F; Goodwin R W; Wright M J; Kerac M; Heads R J; Yellon D M
Myocardial protection after monophosphoryl lipid A: studies of delayed anti-ischaemic properties in rabbit heart.
British journal of pharmacology 1996;117(8):1685-92.
1996: Yellon D M; Baxter G F; Marber M S
Angina reassessed: pain or protector?
Lancet 1996;347(9009):1159-62.
1996: Morris S D; Cumming D V; Latchman D S; Yellon D M
Specific induction of the 70-kD heat stress proteins by the tyrosine kinase inhibitor herbimycin-A protects rat neonatal cardiomyocytes. A new pharmacological route to stress protein expression?
The Journal of clinical investigation 1996;97(3):706-12.
1996: Woolfson R G; Patel V C; Yellon D M
Pre-conditioning with adenosine leads to concentration-dependent infarct size reduction in the isolated rabbit heart.
Cardiovascular research 1996;31(1):148-51.
1996: Cumming D V; Heads R J; Brand N J; Yellon D M; Latchman D S
The ability of heat stress and metabolic preconditioning to protect primary rat cardiac myocytes.
Basic research in cardiology 1996;91(1):79-85.
1996: Baxter G F; Yellon D M
Delayed myocardial protection following ischaemic preconditioning.
Basic research in cardiology 1996;91(1):53-6.
1996: Heads R J; Latchman D S; Yellon D M
The molecular basis of adaptation to ischemia in the heart: the role of stress proteins and anti-oxidants in the ischemic and reperfused heart.
EXS 1996;76():383-407.
1995: Jenkins D P; Steare S E; Yellon D M
Preconditioning the human myocardium: recent advances and aspirations for the development of a new means of cardioprotection in clinical practice.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1995;9(6):739-47.
1995: Speechly-Dick M E; Grover G J; Yellon D M
Does ischemic preconditioning in the human involve protein kinase C and the ATP-dependent K+ channel? Studies of contractile function after simulated ischemia in an atrial in vitro model.
Circulation research 1995;77(5):1030-5.
1995: Heads R J; Latchman D S; Yellon D M
Differential stress protein mRNA expression during early ischaemic preconditioning in the rabbit heart and its relationship to adenosine receptor function.
Journal of molecular and cellular cardiology 1995;27(10):2133-48.
1995: Heads R J; Yellon D M; Latchman D S
Differential cytoprotection against heat stress or hypoxia following expression of specific stress protein genes in myogenic cells.
Journal of molecular and cellular cardiology 1995;27(8):1669-78.
1995: Jenkins D P; Pugsley W B; Yellon D M
Ischaemic preconditioning in a model of global ischaemia: infarct size limitation, but no reduction of stunning.
Journal of molecular and cellular cardiology 1995;27(8):1623-32.
1995: Marber M S; Baxter G F; Yellon D M
Prodromal angina limits infarct size: a role for ischemic preconditioning.
Circulation 1995;92(4):1061-2.
1995: Walker D M; Walker J M; Pugsley W B; Pattison C W; Yellon D M
Preconditioning in isolated superfused human muscle.
Journal of molecular and cellular cardiology 1995;27(6):1349-57.
1995: Baxter G F; Goma F M; Yellon D M
Involvement of protein kinase C in the delayed cytoprotection following sublethal ischaemia in rabbit myocardium.
British journal of pharmacology 1995;115(2):222-4.
1995: Yellon D M; Baxter G F
A "second window of protection" or delayed preconditioning phenomenon: future horizons for myocardial protection?
Journal of molecular and cellular cardiology 1995;27(4):1023-34.
1995: Woolfson R G; Patel V C; Neild G H; Yellon D M
Inhibition of nitric oxide synthesis reduces infarct size by an adenosine-dependent mechanism.
Circulation 1995;91(5):1545-51.
1995: Steare S E; Yellon D M
The potential for endogenous myocardial antioxidants to protect the myocardium against ischaemia-reperfusion injury: refreshing the parts exogenous antioxidants cannot reach?
Journal of molecular and cellular cardiology 1995;27(1):65-74.
1994: Baxter G F; Marber M S; Patel V C; Yellon D M
Adenosine receptor involvement in a delayed phase of myocardial protection 24 hours after ischemic preconditioning.
Circulation 1994;90(6):2993-3000.
1994: Yellon D M; Marber M S
Hsp70 in myocardial ischaemia.
Experientia 1994;50(11-12):1075-84.
1994: Speechly-Dick M E; Mocanu M M; Yellon D M
Protein kinase C. Its role in ischemic preconditioning in the rat.
Circulation research 1994;75(3):586-90.
1994: Steare S E; Yellon D M
Increased endogenous catalase activity caused by heat stress does not protect the isolated rat heart against exogenous hydrogen peroxide.
Cardiovascular research 1994;28(7):1096-101.
1994: Speechly-Dick M E; Baxter G F; Yellon D M
Ischaemic preconditioning protects hypertrophied myocardium.
Cardiovascular research 1994;28(7):1025-9.
1994: Heads R J; Latchman D S; Yellon D M
Stable high level expression of a transfected human HSP70 gene protects a heart-derived muscle cell line against thermal stress.
Journal of molecular and cellular cardiology 1994;26(6):695-9.
1994: Marber M S; Walker J M; Latchman D S; Yellon D M
Myocardial protection after whole body heat stress in the rabbit is dependent on metabolic substrate and is related to the amount of the inducible 70-kD heat stress protein.
The Journal of clinical investigation 1994;93(3):1087-94.
1994: Alkhulaifi A M; Yellon D M; Pugsley W B
Preconditioning the human heart during aorto-coronary bypass surgery.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 1994;8(5):270-5; discussion 276.
1993: Walker D M; Walker J M; Yellon D M
Global myocardial ischemia protects the myocardium from subsequent regional ischemia.
Cardioscience 1993;4(4):263-6.
1993: Steare S E; Yellon D M
The protective effect of heat stress against reperfusion arrhythmias in the rat.
Journal of molecular and cellular cardiology 1993;25(12):1471-81.
1993: Alkhulaifi A M; Pugsley W B; Yellon D M
The influence of the time period between preconditioning ischemia and prolonged ischemia on myocardial protection.
Cardioscience 1993;4(3):163-9.
1993: Marber M S; Latchman D S; Walker J M; Yellon D M
Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction.
Circulation 1993;88(3):1264-72.
1993: Marber M S; Walker J M; Latchman D S; Yellon D M
Attenuation by heat stress of a submaximal calcium paradox in the rabbit heart.
Journal of molecular and cellular cardiology 1993;25(9):1119-26.
1993: Patel V C; Yellon D M; Singh K J; Neild G H; Woolfson R G
Inhibition of nitric oxide limits infarct size in the in situ rabbit heart.
Biochemical and biophysical research communications 1993;194(1):234-8.
1993: Yellon D M; Alkhulaifi A M; Pugsley W B
Preconditioning the human myocardium.
Lancet 1993;342(8866):276-7.
1993: Walker D M; Pasini E; Kucukoglu S; Marber M S; Iliodromitis E; Ferrari R; Yellon D M
Heat stress limits infarct size in the isolated perfused rabbit heart.
Cardiovascular research 1993;27(6):962-7.
1993: Marber M S; Walker D M; Eveson D J; Walker J M; Yellon D M
A single five minute period of rapid atrial pacing fails to limit infarct size in the in situ rabbit heart.
Cardiovascular research 1993;27(4):597-601.
1993: Yellon D M; Latchman D S; Marber M S
Stress proteins--an endogenous route to myocardial protection: fact or fiction?
Cardiovascular research 1993;27(2):158-61.
1992: Yellon D M; Alkhulaifi A M; Browne E E; Pugsley W B
Ischaemic preconditioning limits infarct size in the rat heart.
Cardiovascular research 1992;26(10):983-7.
1992: Yellon D M; Pasini E; Cargnoni A; Marber M S; Latchman D S; Ferrari R
The protective role of heat stress in the ischaemic and reperfused rabbit myocardium.
Journal of molecular and cellular cardiology 1992;24(8):895-907.
1992: Yellon D M; Latchman D S
Stress proteins and myocardial protection.
Journal of molecular and cellular cardiology 1992;24(2):113-24.
1988: Downey J M; Hearse D J; Yellon D M
The role of xanthine oxidase during myocardial ischemia in several species including man.
Journal of molecular and cellular cardiology 1988;20 Suppl 2():55-63.
1988: Miura T; Yellon D M; Kingma J; Downey J M
Protection afforded by allopurinol in the first 24 hours of coronary occlusion is diminished after 48 hours.
Free radical biology & medicine 1988;4(1):25-30.
1987: Downey J M; Miura T; Eddy L J; Chambers D E; Mellert T; Hearse D J; Yellon D M
Xanthine oxidase is not a source of free radicals in the ischemic rabbit heart.
Journal of molecular and cellular cardiology 1987;19(11):1053-60.
1985: Akizuki S; Yoshida S; Chambers D E; Eddy L J; Parmley L F; Yellon D M; Downey J M
Infarct size limitation by the xanthine oxidase inhibitor, allopurinol, in closed-chest dogs with small infarcts.
Cardiovascular research 1985;19(11):686-92.

Sign-in to see more